Article
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Journal of cancer research and clinical oncology - 1 Jan 2021
Masuda Ken, Horinouchi Hidehito, Tanaka Midori, Higashiyama Ryoko, Shinno Yuki, Sato Jun, Matsumoto Yuji, Okuma Yusuke, Yoshida Tatsuya, Goto Yasushi, Yamamoto Noboru, Ohe Yuichiro
Abstract excerpt
INTRODUCTION: Several studies have demonstrated that non-small cell lung cancer patients (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical outcomes in response to treatment with programmed death-1 (PD-1) inhibitors. However, it remains unclear whether EGFR-mutated NSCLCs with a high programmed death-ligand-1 (PD-L1) expression (tumor proportion score ≥ 50%) respond to PD-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.